Pyrosequencing analysis for detection of a BRAFV600E mutation in an FNAB specimen of thyroid nodules

Diagnostic Molecular Pathology

Volumn 17, Issue 2, 2008, Pages 118-125

  Kim, Suk Kyeong ^a   Kim, Dong Lim ^a   Han, Hye Seung ^b   Kim, Wan Seop ^b   Kim, Seung Ja ^c   Moon, Won Jin ^c   Oh, Seo Young ^b   Hwang, Tae Sook ^b,d  

^a Departments of Internal Medicine

^b Departments of Pathology   (South Korea)

^c Konkuk University School of Medicine   (South Korea)

^d Konkuk University Hospital   (South Korea)

Author keywords

BRAF; FNAB; Papillary thyroid carcinoma; Thyroid cancer; Thyroid nodule

Indexed keywords

B RAF KINASE; BRAF PROTEIN, HUMAN; DNA;

ANAPLASTIC CARCINOMA; ARTICLE; ASPIRATION BIOPSY; BENIGN TUMOR; CANCER TISSUE; CONTROLLED STUDY; DIAGNOSTIC VALUE; DNA EXTRACTION; DNA SEQUENCE; FOLLICULAR CARCINOMA; GENE IDENTIFICATION; GENE MUTATION; HUMAN; HUMAN CELL; HUMAN TISSUE; LUNG CARCINOMA; MEDULLARY CARCINOMA; MUTATIONAL ANALYSIS; NODULAR HYPERPLASIA; PAPILLARY CARCINOMA; PRIORITY JOURNAL; PYROSEQUENCING; SEQUENCE ANALYSIS; THYROID CARCINOMA; THYROID HYPERPLASIA; THYROID MEDULLARY CARCINOMA; THYROID NODULE; ADENOCARCINOMA; COMPARATIVE STUDY; ECONOMICS; EVALUATION; GENETICS; METABOLISM; METASTASIS; METHODOLOGY; NEEDLE BIOPSY; NUCLEOTIDE SEQUENCE; PATHOLOGY; POLYMERASE CHAIN REACTION; PREDICTION AND FORECASTING; THYROID TUMOR; TUMOR CELL LINE;

ADENOCARCINOMA; BIOPSY, FINE-NEEDLE; CELL LINE, TUMOR; DNA MUTATIONAL ANALYSIS; DNA, NEOPLASM; HUMANS; POLYMERASE CHAIN REACTION; PREDICTIVE VALUE OF TESTS; PROTO-ONCOGENE PROTEINS B-RAF; THYROID NEOPLASMS; THYROID NODULE;

EID: 47049088152     PISSN: 10529551     EISSN: None     Source Type: Journal    
DOI: 10.1097/PDM.0b013e31815d059d     Document Type: Article

References (38)

1. National Cancer Centre, Korea (2003). 2002 Annual Report of the Korea Central Cancer Registry [WWW document]. Available at: http://www.ncc.re.kr last accessed: February 2005.
2. National Health Insurance Corporation (2007). 2005 Annual Report of Disease Registry. Available at: http://www.nhic.or.kr.
3. Ezzat S, Sarti DA, Cain DR, et al. Thyroid incidentalomas. Prevalence by palpation and ultrasonography. Arch Intern Med. 1994;154:1838-1840.
4. Meier CA. Thyroid nodules: pathogenesis, diagnosis and treatment. Baillieres Best Pract Res Clin Endocrinol Metab. 2000;14:559-575.
5. Kang KW, No JH, Chung JH, et al. Prevalence, clinical and ultrasonographic characteristics of thyroid incidentalomas. Thyroid. 2004;14:29-33.
6. Lee HK, Hur MH, Ahn SM. Diagnosis of occult thyroid carcinoma by ultrasonography. Yonsei Med J. 2003;44:1040-1044.
7. Haugen BR, Woodmansee WW, McDermott MT. Towards improving the utility of fine-needle aspiration biopsy for the diagnosis of thyroid tumors. Clin Endocrinol. 2002;56:281-290.
8. Oertel YC. A pathologist trying to help endocrinologist to interpret cytopathology reports from thyroid aspirates. J Clin Endocrinol Metab. 2002;87:1459-1461.
9. Oertel YC, Burman K, Boyle L, et al. Integrating fineneedle aspiration into a daily practice involving thyroid disorders: the Washington Hospital Center Approach. Diag Cytopathol. 2002;27: 120-122.
10. Davies H, Bignell GR, Cox C, et al. Mutations of the BRAF gene in human cancer. Nature. 2002;417:949-954.
11. Peyssonnaux C, Eychene A. The Raf/MEK/ERK pathway: new concepts of activation. Biol Cell. 2001;93:53-62.
12. Hilger RA, Scheulen ME, Strumberg D. The Ras-Raf-MEK-ERK pathway in the treatment of cancer. Onkologie. 2002;25:511-518.
13. Xing M. BRAF mutation in thyroid cancer. Endocr Relat Cancer. 2005;12:245-262.
14. Kim K, Kang D, Kim S, et al. Mutations of BRAF gene in papillary thyroid carcinoma in a Korean population. Yonsei Med J. 2004;45: 818-821.
15. Kim TY, Kim WB, Rhee YS, et al. The BRAFV600E mutation is useful for prediction of clinical recurrence in low-risk patients with conventional papillary thyroid carcinoma. Clin Endocrinol. 2006;65: 364-368.
16. Chung KW, Yang SK, Lee GK, et al. Detection of BRAF600E mutation on fine needle aspiration specimens of thyroid nodule refines cyto-pathology diagnosi, especially in BRAF600E mutation-prevalent area. Clin Endocrinol (Oxf). 2006;65:660-666.
17. Kimura ET, Nikiforova MN, Zhu Z, et al. High prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinoma. Cancer Res. 2003;63:1454-1457.
18. Fukushima T, Suzuki S, Mashiko M, et al. BRAF mutations in papillary carcinomas of the thyroid. Oncogene. 2003;22:6455-6457.
19. Hayashida N, Namba H, Kumagai A, et al. A rapid and simple detection method for the BRAF (T1796A) mutation in fine-needle aspirated thyroid carcinoma cells. Thyroid. 2004;14:910-915.
20. Melillo RM, Castellone MD, Guarino V, et al. The RET/PTC-RASBRAF linear signaling cascade mediates the nmotile and mitogenic phenotype of thyroid cancer cells. J Clin Invest. 2005;115: 1068-1081.
21. Park KY, Koh JM, Kim YI, et al. Prevalences of Gs alpha, ras, p53 mutations and RET/PTC rearrangement in differentiated thyroid tumors in a Korean population. Clin Endocrinol. 1998; 49:317-323.
22. Chung JH, Hahm JR, Min YK, et al. Detection of RET/PTC oncogene rearrangement in Korean papillary thyroid carcinomas. Thyroid. 1999;9:1237-1243.
23. Agaton C, Unneberg P, Sievertzon M, et al. Gene expression analysis by signature pyrosequencing. Gene. 2002;289:31-39.
24. Fakhrai-Rad H, Pourmand N, Ronaghi M. Pyrosequencing: an accurate detection platform for single nucleotide polymorphisms. Hum Mutat. 2002;19:479-485.
25. Garcia CA, Ahmadian A, Gharizadeh B, et al. Mutation detection by pyrosequencing: sequencing of exons 5-8 of the p53 tumor suppressor gene. Gene. 2000;253:249-257.
26. Ahmadian A, Gharizadeh B, Gustafsson AC, et al. Single-nucleotide polymorphism analysis by pyrosequencing. Anal Bio-chem. 2000;280:103-110.
27. Spittle C, Ward MR, Nathanson KL, et al. Application of a BRAF pyrosequencing assay for mutation detection and copy number analysis in malignant melanoma. J Mol Diagn. 2007;9:464-471.
28. Koh CS, Ku JL, Park SY. Establishment and characterization of cell lines from three human thyroid carcinomas: responses to all-trans-retinoic acid and mutations in the BRAF gene. Mol Cell Endocrinol. 2007:264;118-127.
29. Salvatore G, Giannini R, Faviana P, et al. Analysis of BRAF point mutation and RET/PTC rearrangement refines the fine-needle aspiration diagnosis of papillary thyroid carcinoma. J Clin Endocrinol Metab. 2004;89:5175-5180.
30. Jarry M, Masson D, Cassagnau E, et al. Real time allele-specific amplification for sensitive detection of BRAF mutation V600E. Mol Cell Probes. 2004;18:349-352.
31. Jin L, Sebo TJ, Nakamura N, et al. BRAF mutation analysis in fine needle aspiration (FNA) cytology of the thyroid. Diagn Mol Pathol. 2006;15:136-143.
32. Ball ED, Mills LE, Neubauer A, et al. Detection of minimal acute myeloid leukemia cells in bone marrow by probing for mutated ras oncogenes using the polymerase chain reaction. Prog Clin Biol Res. 1990;333:499-506.
33. Cogswell PC, Morgan R, Dunn M, et al. Mutations of the ras protooncogenes in chronic myelogenous leukemia: a high frequency of ras mutations in bcr/abl rearrangement-negative chronic myelo-genous leukemia. Blood. 1989;74:2629-2633.
34. Mane SM, Meltzer SJ, Gutheil JC, et al. RAS gene activation in acute myelogenous leukemia: analysis by in vitro amplification and DNA base sequence determination. Genes Chromosomes Cancer. 1990;2:71-77.
35. Ronaghi M, Uhlen M, Nyren P. A sequencing method based on real-time pyrophosphate. Science. 1998;281:363-365.
36. Lumachi F, Borsato S, Treqnaghi A, et al. Accuracy of fine-needle aspiration cytology and frozen-section examination in patients with thyroid cancer. Biomed Pharmacother. 2004;58: 56-60.
37. Brookks AD, Shaha AR, DuMornay W, et al. Role of fine-needle aspiration biopsy and frozen section analysis in the surgical management of thyroid tumors. Ann Surg Oncol. 2001;8: 92-100.
38. Chao TC, Lin JD, Chao HH, et al. Surgical treatment of solitary thyroid nodules via fine-needle aspiration biopsy and frozen-section analysis. Ann Surg Oncol. 2007;14:712-718.